Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus LEVOTHYROXINE SODIUM INTRAVENOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus LEVOTHYROXINE SODIUM INTRAVENOUS.
LEVOLET vs LEVOTHYROXINE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Category C
Category A/B
Thyroid Hormone
Thyroid Hormone